

Cardiovascular system

Hypertension (High Blood Pressure)

Introduction / Epidemiology

- Hypertension (HTN) is defined as persistently elevated arterial blood pressure.
- According to **2020 ISH and 2017**
 - **ACC/AHA guidelines:**
 - **Normal BP:** <120/80 mmHg
 - **Elevated BP:** 120–129/<80 mmHg
 - **Stage 1 HTN:** 130–139 systolic or 80–89 diastolic mmHg
 - **Stage 2 HTN:** ≥140 systolic or ≥90 diastolic mmHg

Epidemiology:

- Affects **~1.28 billion** people worldwide (WHO 2021).
- Leading **modifiable risk factor** for CVD, stroke, renal disease.
- Prevalence increases with **age**, more common in **males** <60 years, then in **females** >60 years.
- High in **low- and middle-income countries** due to poor diagnosis and control.
- Only **~20%** of hypertensives have controlled BP.

Etiopathogenesis

Primary (Essential) Hypertension – ~90–95%:

- No identifiable cause; multifactorial.
- Contributing factors:
 - Genetic predisposition (e.g., polymorphisms in RAAS genes)
 - Overactivation of **renin-angiotensin-aldosterone system (RAAS)**
 - Sympathetic nervous system hyperactivity
 - Sodium retention
 - Obesity, insulin resistance
 - Environmental (salt intake, stress, sedentary lifestyle)

Secondary Hypertension – ~5–10%:

- Identifiable cause:
 - **Renal** (e.g., CKD, renal artery stenosis)
 - **Endocrine** (e.g., primary aldosteronism, pheochromocytoma, Cushing's)

- **Vascular** (e.g., coarctation of aorta)
- **Drugs** (NSAIDs, corticosteroids, oral contraceptives)
- **OSA (Obstructive Sleep Apnea)**

Clinical Features / Symptoms

Often asymptomatic (“Silent killer”)

When present:

- Headache (esp. occipital, morning)
- Dizziness, fatigue
- Palpitations
- Epistaxis
- Blurred vision
- Symptoms due to end-organ damage:
 - Chest pain (cardiac ischemia)
 - Dyspnea (CHF)
 - Hematuria (renal involvement)
 - Neurological symptoms (stroke, TIA)

Diagnosis & Investigations

Diagnosis:

1. Based on **2–3 elevated readings** on **different occasions**.
2. Use validated **automated BP devices**.
3. Measure in both arms, after 5 minutes rest, seated, proper cuff size.

Investigations:

Basic work-up (for all):

- CBC
- Fasting blood glucose / HbA1c
- Lipid profile
- Serum creatinine, eGFR
- Serum electrolytes (K⁺, Na⁺)
- Urinalysis (proteinuria, RBCs)
- ECG
- Optional: echocardiogram (LVH), fundus exam (retinopathy)

Secondary HTN work-up (if suspected):

- Renal Doppler USG
- Plasma aldosterone-renin ratio (ARR)
- 24-hour urine catecholamines/metanephrines
- Thyroid profile
- Sleep study (for OSA)

Treatment Goals / Therapeutic Objectives

- Reduce BP to **target level** to minimize risk of cardiovascular events and organ damage.
- **BP Targets:**
 - <140/90 mmHg for most
 - <130/80 mmHg in patients with **diabetes, CKD, CAD, stroke**
 - 65 years: <140–150/90 (avoid hypotension)
- **Long-term goals:**
 - Prevent MI, stroke, heart failure, CKD
 - Reverse LVH
 - Improve quality of life

Non-Pharmacological Therapy

- **Lifestyle modifications – cornerstone for all stages:**
 - **DASH diet:** Rich in fruits, vegetables, low-fat dairy; reduced saturated fats
 - **Salt restriction:** <5g/day sodium (~2g Na⁺)
 - **Weight reduction:** BMI <25 kg/m²
 - **Physical activity:** 150 min/week moderate exercise
 - **Alcohol moderation:** <2 drinks/day (men), <1 drink/day (women)
 - **Smoking cessation**
 - **Stress management:** Yoga, meditation
- Can reduce SBP by 4–11 mmHg depending on intervention.

Pharmacological Therapy

First-line Drugs

- (as per ACC/AHA, ESC, ISH guidelines):
 - Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone)
 - ACE inhibitors (e.g., enalapril, ramipril)

- ARBs (e.g., losartan, telmisartan)
- Calcium channel blockers (CCBs) (e.g., amlodipine, nifedipine)
- Use combination therapy for stage 2 HTN or initial BP >20/10 mmHg above target.

Alternative Drugs:

- **Beta-blockers:** Used in CAD, heart failure, arrhythmias.
- **Loop diuretics:** In CKD or CHF with edema.
- **Alpha-blockers:** Resistant HTN, BPH (e.g., prazosin).
- **Centrally acting agents:** (e.g., clonidine, methyldopa – pregnancy)

Drug Details Example (for common agents):

Drug	Dose	Mechanism	Rationale
Amlodipine	5–10 mg OD	Dihydropyridine CCB; vasodilation	Effective in elderly, low renin states
Ramipril	2.5–10 mg OD	ACE inhibition → ↓Ang II	Preferred in diabetics, CKD
Chlorthalidone	12.5–25 mg OD	Inhibits Na-Cl reabsorption in DCT	Long half-life, CV protection
Losartan	50–100 mg OD	ARB, blocks AT1 receptor	Use if ACEI not tolerated (e.g., cough)

Individualized Patient-Specific Therapeutic Plan

- **Age:** Elderly – start low, go slow; avoid orthostatic hypotension.
- **Diabetes:** ACEI/ARB to protect kidneys.
- **CKD:** ACEI/ARB if albuminuria; loop diuretics if volume overload.
- **CAD/MI:** Beta-blockers + ACEI/ARB
- **Pregnancy:** Methyldopa, labetalol, nifedipine
- **African descent:** Better response to CCBs and thiazides
- **Asthma/COPD:** Avoid non-selective beta-blockers
- **Gout:** Avoid thiazides (can increase uric acid)
- **Liver disease:** Avoid centrally acting drugs (e.g., methyldopa – hepatotoxic)

Controversies / Special Considerations

A. BP Targets Debate:

- **SPRINT trial (2015):** Intensive control (<120 mmHg) reduced CV events but increased adverse effects (syncope, AKI).
- Recent guidelines (e.g., ESC/ESH 2023) lean towards individualized targets.

B. Choice of first drug:

- Some debate on superiority of ACEI vs CCB vs thiazides.
- ALLHAT trial showed similar CV outcomes among classes.

C. White-coat & Masked HTN:

- Home/ambulatory BP monitoring essential for accurate diagnosis.

D. Resistant HTN:

- Defined as BP uncontrolled despite 3 drugs (including diuretic).
- Evaluate for secondary causes.

Monitoring Therapy

Clinical Parameters:

- BP (home and office) every 2–4 weeks initially, then every 3–6 months
- Symptom review: dizziness, fatigue, hypotension signs

Laboratory:

- Electrolytes, renal function: 1–2 weeks after starting ACEI/diuretics
- Lipid profile, glucose: Annually or as needed

Response Timeline:

- BP lowering begins in 1–2 weeks, max effect at 4–6 weeks
- Long-term: Monitor for regression of LVH, proteinuria, etc.

Adverse Effects & Management

Drug Class	Adverse Effects	Management
ACEIs	Cough, angioedema, ↑K ⁺ , AKI	Switch to ARB; monitor labs
ARBs	Hyperkalemia, dizziness	Monitor K ⁺ , adjust dose
Thiazides	HypoK, hypoNa, hyperuricemia	K ⁺ supplements, monitor labs
CCBs	Pedal edema, headache	Switch to ARB, combine with ACEI
Beta-blockers	Bradycardia, fatigue, ED	Titrate slowly, avoid in asthma

Follow-up and Patient Counseling

Follow-Up:

- Review BP, lab values, lifestyle at each visit
- Reassess drug response every 2–4 weeks
- Annual ECG, eye exam, urine microalbumin



FREE PREVIEW

[Click here to visit our website](#)

PHARMACY PREMIUM NOTES

Complete subject
and semesters are
available on
FirstHope app only.



[Scan or click here](#)

Click here to get the app



Available on Google Play

JOIN THE FIRSTHOPE COMMUNITY

Join our Telegram channel

Click here to join Telegram



[Scan or click here](#)

@FirstHopeNotes

Instagram

@firsthope.official

[Click here to follow >](#)

YouTube channel

FirstHope-Pharmacy / Live streams

[Click here to watch >](#)

WhatsApp channel

Follow FirstHope on WhatsApp

[Click here to join >](#)

FirstHope website

firsthopenotes.com

[Click here to visit >](#)

B.Pharm / D.Pharm / M.Pharm / Pharm.D

Preview notes. Complete subjects and semesters in the FirstHope app.